1X Announces Strategic Partnership to Make up to 10,000 Humanoid Robots Available to EQT’s Global Portfolio
11.12.2025 16:00:00 EET | Business Wire | Press release
1X, the AI and robotics company behind NEO, the first ready-to-ship humanoid robot, today announced a strategic partnership with EQT, one of the world’s largest private equity firms and an investor in 1X through EQT Ventures. The partnership marks the beginning of what could become a large-scale commercial rollout of general-purpose humanoid robots across multiple industries.
Together, 1X and EQT have a shared intent to facilitate the rollout of up to 10,000 humanoids across EQT’s global portfolio companies between 2026 and 2030, with any potential implementation decision ultimately taken by each portfolio company. The partnership represents an early step in bringing humanoid robotics into mainstream commercial use.
Through this collaboration, EQT’s portfolio companies will gain early access to 1X’s commercial production capacity and integration expertise, giving early adopters a first-mover advantage in addressing structural workforce transformation. The partnership will focus on high-impact use cases for robots working closely with humans, such as industrial software, logistics, facility operations, warehousing, manufacturing, and healthcare.
1X will launch pilots in the United States in 2026, followed by rapid scaling across Europe and Asia.
“This partnership brings humanoid robotics into the real economy,”said Bernt Øivind Børnich, Founder and CEO of 1X. “EQT’s global reach and operational expertise make them the ideal partner to help deploy our technology safely, responsibly, and at scale. Together, we aim to demonstrate how humanoid robots can enhance productivity, improve safety, and create more sustainable labor models worldwide.”
“Humanoid robotics is moving from fiction to real-world deployment, and 1X is uniquely positioned to lead the next wave of mass-market robotic adoption,” said Ted Persson, lead Partner in EQT Ventures, which first invested in 1X in 2023. “This isn’t about replacing people, it’s about giving them superpowers. By making 1X’s technology available to our portfolio companies, we help them tackle labor shortages, improve safety, and unlock new levels of productivity in the industries that keep the world running.”
Key Highlights
- Up to 10,000 humanoids made available for deployment across EQT’s 300+ portfolio companies (2026–2030), with any potential implementation decided by each portfolio company
- Focus on logistics, facility operations, warehousing, manufacturing, and healthcare
- Joint ambition for safe, responsible, and human-centered deployment
The partnership underscores a shared vision between EQT and 1X: a future where humanoid robots work alongside people, supporting industrial resilience and enhancing productivity. With this announcement, 1X strengthens its position as a frontrunner in the global race to commercialize general-purpose humanoid robots at scale.
About 1X
1X is a leading U.S.-based AI and robotics company, developing NEO – the humanoid robot. 1X’s mission is to create an abundant future through safe, intelligent humanoids. The humanoid platform from 1X has been designed to operate amongst humans. From homes to manufacturing floors, 1X provides an artificial labor solution to enhance human potential.
About EQT
EQT is a global investment organization with a clear purpose and €267 billion in assets under management as of 30 September 2025. The platform spans Private Capital and Real Assets and includes about 300 portfolio companies with roughly 700,000 employees. EQT also owns more than 2,000 real estate assets across the US, Europe, and Asia Pacific, including 1,800 logistics tenants and 20,000 living tenants. Its infrastructure portfolio supports 330 million passengers each year, serves 40 million users of social infrastructure services, operates more than 70 data centers, and includes over 145 clinics. More info: www.eqtgroup.com
EQT Ventures
EQT Ventures is an early-stage lead investor striving to be the most impactful partner to generation-defining founders. Since launch, EQT Ventures has raised over €2.6 billion across its funds and partnered with more than 140 founding teams across Europe and the US to build enduring, category-defining companies. The team provides more than capital, offering deep operational expertise, strategic guidance, and access to EQT’s global platform to accelerate growth. With a team of former founders and operators, EQT Ventures delivers radical support to help startups scale with confidence. EQT Ventures is part of EQT Group and, together with EQT Growth, forms EQT’s early-stage tech platform. https://eqtgroup.com/private-capital/eqt-ventures
View source version on businesswire.com: https://www.businesswire.com/news/home/20251211360340/en/
Contacts
Media Contact:
Kendall Pennington
Head of Communications, 1X
Email: press@1x.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom